Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


IPO Report: Prosensa Holding B.V.

By  +Follow June 27, 2013 11:50AM
Tickers Mentioned:

Based in Leiden, NL, Prosensa Holding B.V. (RNA) scheduled a $60 million IPO with a market capitalization of $408 million, at a price range mid-point of $12 for Friday, June 28, 2013.

  • F1-A filed June 18, 2013
  • Manager, Joint Managers: J.P. Morgan; Citi
  • Co-Managers: Leerink Swann; Wedbush PacGrow; KBC Securities; Trout Capital


RNA is working on a medical solution to Duchenne muscular dystrophy (DMD), a genetic disease. DMD occurs mostly in boys. Symptoms typically appear between ages 1-4 years old.

The results of clinical trials may indicate that drisapersen may lead to stabilization of the disease. But stabilization is not a molecular cure, which is what some of the recent stem cell IPOs seem to offer as a possiblity.

Another company, PTCT, focuses on a different subset of DMD and was up 10% on its IPO on Thursday, June 20, 2013.

RNA reports in Eurodollars, so to do any financial analysis in the U.S. dollars it's necessary to convert to dollars.


100% of revenue comes from licensing and collaboration agreements with GlaxoSmithKline (GSK), and RNA works closely with Leiden University Medical Center (LUMC)


Post-IPO RNA will have $107 million in cash. The ratio of cash to market capitalization will be 26%, at the price point mid-point of $12. RNA's accumulated deficit is $56 million.

Valuation Ratios

IPO Mrkt

Price /

Price /

Price /

Price /

% offered

annualizing Q1 '13

Cap (MM)





in IPO

Prosensa Holding B.V. (RNS)









Relative to price-to-book ratios, RNA is priced at about double PTCT, which IPO'd June 20. Although some IPO watchers believe RNA will go up on the IPO, it seems product to avoid RNA based on the comparison with PTCT.

To put the above conclusions and observations in context, the following is reorganized, edited and summarized from the full S-1 referenced earlier:


RNA is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders.

RNA's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease.

RNA"s clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy, or DMD. Each of RNA's DMD compounds has been granted orphan drug status in the United States and the European Union.

About DMD

RNA is working on a medical solution to Duchenne muscular dystrophy , a genetic disease. DMD occurs mostly in boys. Symptoms typically appear between ages 1-4 years old. The main sign of DMD is muscle weakness that worsens over time. Before age five, the muscles in the legs, arms, and trunk begin to weaken. Later in the disease the heart and respiratory muscles weaken.

DMD is a progressive, serious disease and is caused by a genetic mutation. The mutation causes the gene to make inadequate amounts of a protein called dystrophin. This protein is needed to keep muscles intact.

Collaboration with GlaxoSmithKline

In 2009, RNA entered into an exclusive worldwide collaboration with GSK for the development and commercialization of RNA-based therapeutics for DMD, with GSK exclusively licensing worldwide rights to develop and commercialize drisapersen and obtaining an option to exclusively license PRO044.

In addition, GSK has the option to exclusively license either PRO045 or PRO053 and the further option to exclusively license either PRO052 or PRO055. PRO045 is paired with PRO053, and PRO052 is paired with PRO055, because each product candidate in the respective pairings addresses a similar-sized patient sub-population and is at a comparable stage of development.

RNA will retain the full rights to the product candidates that are not licensed by GSK, and for each product candidate licensed by GSK from each of the pairings of product candidates described above, RNA will retain the option to certain commercial rights in a selected European territory. All of other DMD compounds fall outside of the scope of the agreement, and RNA intends to develop and commercialize them or consider partnerships.

GSK financial terms

Upon entering into the agreement with GSK, RNA received a $23 million nonrefundable upfront payment from GSK and RNA has received $63.5 million in total under the agreement. Including amounts already paid, RNA is eligible for up to $677 million in total milestone payments under the agreement.

RNA is also entitled to receive percentage royalties in the low teens on future global sales of drisapersen and each of the other compounds that GSK licenses and successfully commercializes.

More about DMD

DMD is one of the most prevalent rare genetic diseases globally affecting up to 1 in 3,500 boys and is invariably fatal. There is currently no approved disease-modifying therapy for DMD. The progressive muscle-wasting that characterizes this disease is caused by inadequate production of dystrophin, a protein necessary for muscle function, as a result of mutations in the dystrophin gene. The different mutations, which are mostly deletions of one or more exons, found in the dystrophin gene result in distinct sub-populations of DMD patients.

RMA is designing product candidates to address several sub-populations using RNA's platform technology. The first product candidate, drisapersen, can address a variety of mutations in the dystrophin gene, such as a deletion of exon 50 or exons 48 to 50.

RNA financing

Since 2002, RNA raised $75.6 million from private placements of equity securities, including to a number of venture capital firms. In addition, RNA has received grants and loans from several DMD-focused patient advocacy organizations to support research of therapies for DMD. As of March 31, 2013, RNA had $48 million in cash and cash equivalents.

Clinical development

Drisapersen is being developed in collaboration with GlaxoSmithKline, or GSK. Drisapersen aims to restore dystrophin expression and improve muscle condition and function in the largest known sub-population of DMD patients.

In clinical trials, drisapersen has been shown to produce dystrophin expression and have a beneficial therapeutic effect on DMD patients. A Phase II placebo-controlled study of drisapersen in 53 DMD patients was completed and demonstrated a statistically significant and clinically important difference in the primary endpoint, which was the distance walked in the six minute walk test, or 6MWD, between the placebo group and the continuous active-treatment group at a dose of 6 mg/kg/week after 24 weeks.

This clinically meaningful benefit was maintained after 48 weeks of treatment, and drisapersen was well tolerated throughout the duration of this study. Preliminary results suggest that treatment with drisapersen was in general associated with increased levels of dystrophin expression when compared with pre-treatment levels.

Drisapersen successfully completed a twelve-patient Phase I/II study, and all patients were enrolled in an open-label extension study which has been ongoing since August 2009. The results indicate that drisapersen may lead to stabilization of the disease, as evidenced by an improvement or a slower than expected decline in the 6MWD, and the ongoing study continues to provide safety and tolerability data.

A pivotal Phase III study of drisapersen was initiated in December 2010, and results are expected in the fourth quarter of 2013. This study is a randomized, double-blind and placebo-controlled trial, assessing drisapersen at a dose of 6 mg/kg/week in 186 boys. The primary endpoint is the 6MWD at 48 weeks.

To date, over 300 patients have participated in clinical studies of drisapersen at more than 50 trial sites in 25 countries, and patient retention rates through March 2013 averaged 96% across all drisapersen clinical studies.

Follow-on DMD compounds

PRO044, the next most advanced product candidate, addresses a separate sub-population of DMD patients. RNA developed PRO044 using our exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.

PRO044 is currently in a Phase I/II study in Europe, which RNA expects to complete in the second half of 2013. RNA has four additional earlier-stage compounds that address other distinct sub-populations of DMD patients.

Of these, PRO045 entered clinical trials in the first quarter of 2013, and DMD anticipates that PRO053 will enter clinical trials in mid-2013. PRO052 and PRO055 are in advanced preclinical development.

RNA has started a research program, PROSPECT, which includes a new and innovative application of RNA's exon-skipping technology platform to specifically target rarer mutations in the dystrophin gene.

Intellectual property

RNA has entered into a collaboration arrangement with LUMC for the reciprocal licensing of RNA's and LUMC's individual and joint intellectual property rights in relation to certain patent rights and know-how rights, which have been the basis of RNA's research and development of treatment targeting DMD.

5% shareholders pre-IPO

ABV IV Holdings N.V., 21.4%
LSP Prosensa Pooling B.V., 21.4%
New Enterprise Associates 13, L.P., 20.8%
Gimv N.V., 9%
Idinvest Partners, 9%
MedSciences Prosensa Holding B.V., 6.9%

Use of proceeds

RNA expects to net $53 million from its IPO.

RNA currently expects that it will use the net proceeds from this offering, together with cash and cash equivalents on hand, as follows:

• $82 million to fund the current DMD development portfolio for which RNA bears expenses (PRO045, PRO053, PRO052 and PRO055), PROSPECT and DMD-support projects, including the DMD natural history study;

• $11 million to fund non-DMD projects, including DM1 and HD; and

• the remainder for working capital and other general corporate purposes.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for RNA
28 Jan 15 05:48:00
Yesterday's Top O.I. Decreases [01.27.15] $RY $RNA $SMFG $TSLA $BAC $FXCM $TRP $BP http://t.co/fsBqmWN4Kt
27 Jan 15 16:48:47
Largest%Inc SI: $adxs $tkmr $biod $shpg $edap $vrml $mdco $alks $cnat Largest%Dec: $rna $atos $ontx $npsp $psti $aldr http://t.co/8HwrKUbTId
Kid Dynamite
27 Jan 15 11:44:29
this is the only thing I can come up with regards to the $RNA put prices - some weird Dutch tax thing? who knows http://t.co/lqeSE7gm2w
Kid Dynamite
27 Jan 15 10:35:12
can some options guru explain the $RNA put prices to me? ie: Jan 2016 $17 puts: $1.10 bid... Aug 2015 $16 puts, 35c bid. ???
27 Jan 15 07:32:02
Trending #Biotech topics include $RNA, $MNTA, #Valtrex #stocks #invest See more http://t.co/EpbbdrcRcF
27 Jan 15 03:05:36
Largest O.I. Decreases [01.26.15] $RY $RNA $SU $CVRR $LINE $GE $SNE $FCX $BP http://t.co/RxdHBFn82d
Breaking News
26 Jan 15 12:55:03
$RNA: New SEC Filing for RNA: Form SC 13D, No. 0001193125-15-020293 http://t.co/w4GNPOGqlo http://t.co/pbGx5orViy
Penny Stock Secret
26 Jan 15 07:08:53
This Guy Turned $100 into over $10,000 In Just 30 Days! http://t.co/vezCDY95do .. $ATOS $HIFS $RNA
25 Jan 15 12:21:28
RT @SubPennyPlays: VRCI Scientific Research & Development Team Manit Patel, Chief Technology Officer Manit Patel earned a Ba $RNA $VRCI ht…
The Legacy News
25 Jan 15 09:12:45
Prosensa Holding NV Receives $16.54 Average PT from Analysts $RNA http://t.co/KaEOquqHUe
25 Jan 15 04:20:35
Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystorphy #dmd #TALEN #CRISPR $srpt $rna $ptct http://t.co/GY6dVO2Mt2
23 Jan 15 14:24:00
RT @portefeuillefun: $TTPH and $CEMP added, all emerging markets positions and $RNA position closed. Little change overall. #BBBiotech $BIO…
23 Jan 15 13:11:06
$RNA: Brokerage Firm Price Target on Prosensa Holding NV: http://t.co/0ZFKuMlgc5
V.S. Schulz
22 Jan 15 22:13:32
$TTPH and $CEMP added, all emerging markets positions and $RNA position closed. Little change overall. #BBBiotech $BION $BBZA
John Hall
22 Jan 15 14:11:32
RT @brockskretting: What remains to be determined with $SRPT is what happens when it's administered on diagnosis - $RNA seems a bit toxic t…
22 Jan 15 09:35:16
Prosensa Holding NV Receives $16.54 Consensus PT from Analysts $RNA http://t.co/9o1GJjEZ83
Brock Skretting
22 Jan 15 06:55:55
What remains to be determined with $SRPT is what happens when it's administered on diagnosis - $RNA seems a bit toxic to give to a 5 y/o.
Roy Friedman
22 Jan 15 05:38:37
@jq1234t @bradloncar *Net* proceeds are ~$855M assuming exercise of underwriter's option—just enough4 $RNA deal in most expensive scenario.
Catalyst Trader
21 Jan 15 14:28:20
@nixon786 @bradloncar Maybe they will buy $SRPT for $2 in the rubbish sale basket on drug failure like $RNA. Same nothing to lose strategy
j l
21 Jan 15 13:22:09
$BMRN @MauriceOnTW Doesn't look deals panned out. Made case 4 $RNA purchase and raised $
David Sobek
21 Jan 15 13:16:32
@bradloncar @sharkbiotech Couldn't this just be cash to replenish after the $RNA deal or have they already taken care of that?
21 Jan 15 13:13:48
@bradloncar brad, may be they are planning to buy $SRPT on the top of $RNA
David Jorgensen
21 Jan 15 12:44:00
MT @leon_melens: @Prosensa_RNA @hansschikan leaves as CEO but stays on as Supervisory Brd memb #duchenne $RNA $BMRN http://t.co/L4ghdr5LQW
Livevol Community
21 Jan 15 05:00:06
IV30(TM) GAINER $RNA +158.92% $HLSS +54.64% $OCN +31.19% $MCRL +28.51% $CREE +22.36% $ADXS +21.43% $BWP +20.93% http://t.co/gwzPxhFaBv
21 Jan 15 03:36:02
$BMRN $RNA: State Of The Union Lights Up Biotech: http://t.co/irJApPydx4
21 Jan 15 03:26:48
State Of The Union Lights Up Biotech $BMRN $CBST $FM $RNA http://t.co/rIl065cUQS #SOTU http://t.co/CmduvF85gD
20 Jan 15 20:31:49
Largest OI Decreases - 01.20.2015 - $RY $AAPL $NG $NAT $RNA $RYE $INVE http://t.co/MvsnnDdTGG
By  +Follow June 27, 2013 11:50AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.